BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15072598)

  • 1. Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer.
    Tanaka F; Yanagihara K; Otake Y; Miyahara R; Wada H
    Cancer Sci; 2004 Apr; 95(4):371-6. PubMed ID: 15072598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
    Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
    Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials.
    Hamada C; Tsuboi M; Ohta M; Fujimura S; Kodama K; Imaizumi M; Wada H
    J Thorac Oncol; 2009 Dec; 4(12):1511-6. PubMed ID: 19875974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
    Nakagawa T; Tanaka F; Takata T; Matsuoka K; Miyahara R; Otake Y; Yanagihara K; Fukushimab M; Wada H
    J Surg Oncol; 2002 Oct; 81(2):87-92. PubMed ID: 12355409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study.
    Nakagawa M; Tanaka F; Tsubota N; Ohta M; Takao M; Wada H;
    Ann Oncol; 2005 Jan; 16(1):75-80. PubMed ID: 15598942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
    Miyoshi T; Kondo K; Toba H; Yoshida M; Fujino H; Kenzaki K; Sakiyama S; Takehisa M; Tangoku A
    Anticancer Res; 2007; 27(4C):2641-8. PubMed ID: 17695427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery.
    Wada H; Hitomi S; Teramatsu T
    J Clin Oncol; 1996 Apr; 14(4):1048-54. PubMed ID: 8648356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer.
    Tanaka F; Otake Y; Yanagihara K; Yamada T; Miyahara R; Kawano Y; Li M; Inui K; Wada H
    Br J Cancer; 2001 Jan; 84(2):263-9. PubMed ID: 11161386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A small randomized phase III single-center trial on postoperative UFT administration in patients with completely resected non-small cell lung cancer.
    Ueda H; Sakada T; Kuwahara M; Motohiro A
    Anticancer Drugs; 2004 Jan; 15(1):29-33. PubMed ID: 15090740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
    Tsuchiya T; Kamohara R; Muraoka M; Nagayasu T; Saeki S; Takenoyama M; Suzuki M; Inada K; Tokunaga S; Hayashi T; Urabe S; Koga T; Akamine S; Sugio K
    BMC Cancer; 2020 Dec; 20(1):1192. PubMed ID: 33276755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and Efficacy of Sequential Chemotherapy in Patients with p-stage I Non-small Cell Lung Cancer that Recurring during Postoperative Tegafur-Uracil Adjuvant Chemotherapy.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Invest; 2018; 36(8):424-430. PubMed ID: 30234395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG).
    Wada H; Miyahara R; Tanaka F; Hitomi S
    Eur J Cardiothorac Surg; 1999 Apr; 15(4):438-43. PubMed ID: 10371118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil-tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial.
    Soh J; Toyooka S; Okumura N; Nakamura H; Nakata M; Yamashita M; Sakamoto J; Aoe M; Hotta K; Morita S; Date H
    Int J Clin Oncol; 2019 Nov; 24(11):1367-1376. PubMed ID: 31312931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
    Imaizumi M;
    Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery.
    Endo C; Saito Y; Iwanami H; Tsushima T; Imai T; Kawamura M; Kondo T; Koike K; Handa M; Kanno R; Fujimura S;
    Lung Cancer; 2003 May; 40(2):181-6. PubMed ID: 12711119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT.
    Nakano J; Huang C; Liu D; Masuya D; Nakashima T; Yokomise H; Ueno M; Wada H; Fukushima M
    Br J Cancer; 2006 Sep; 95(5):607-15. PubMed ID: 16880781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.
    Kato H; Ichinose Y; Ohta M; Hata E; Tsubota N; Tada H; Watanabe Y; Wada H; Tsuboi M; Hamajima N; Ohta M;
    N Engl J Med; 2004 Apr; 350(17):1713-21. PubMed ID: 15102997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of angiopoietins and its clinical significance in non-small cell lung cancer.
    Tanaka F; Ishikawa S; Yanagihara K; Miyahara R; Kawano Y; Li M; Otake Y; Wada H
    Cancer Res; 2002 Dec; 62(23):7124-9. PubMed ID: 12460935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative adjuvant chemotherapy for non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. The Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy.
    Wada H; Tanaka F; Hitomi S
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):98-102. PubMed ID: 9348578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor angiogenesis in predicting the survival of patients with stage I lung cancer.
    Medetoglu B; Gunluoglu MZ; Demir A; Melek H; Buyukpinarbasili N; Fener N; Dincer SI
    J Thorac Cardiovasc Surg; 2010 Nov; 140(5):996-1000. PubMed ID: 20708755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.